Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
82.57
-1.21 (-1.44%)
At close: Jan 8, 2025, 4:00 PM
83.00
+0.43 (0.52%)
After-hours: Jan 8, 2025, 4:13 PM EST
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 123.23, with a low estimate of 105 and a high estimate of 150. The average target predicts an increase of 49.24% from the current stock price of 82.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 7 | 7 |
| Buy | 5 | 6 | 6 | 6 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +61.08% | Jan 6, 2025 |
| Mizuho | Mizuho | Buy Maintains $124 → $122 | Buy | Maintains | $124 → $122 | +47.75% | Dec 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +57.44% | Dec 30, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $121 | Buy | Reiterates | $121 | +46.54% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
392.07M
from 270.60M
Increased by 44.89%
Revenue Next Year
660.28M
from 392.07M
Increased by 68.41%
EPS This Year
-5.54
from -5.27
EPS Next Year
-2.13
from -5.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 412.7M | 810.5M | 1.8B | |||
| Avg | 392.1M | 660.3M | 1.1B | |||
| Low | 371.1M | 525.2M | 835.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.5% | 106.7% | 165.3% | |||
| Avg | 44.9% | 68.4% | 69.5% | |||
| Low | 37.2% | 34.0% | 26.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.15 | 0.21 | 9.03 | |||
| Avg | -5.54 | -2.13 | 3.34 | |||
| Low | -5.92 | -4.04 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.